Search

Your search keyword '"Robert J"' showing total 3,997 results
Start Over Author "Robert J" Journal blood
3,997 results on '"Robert J"'

1. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Author

Koshy, Anita G., Kim, Haesook T., Liegel, Jessica, Arnason, Jon, Ho, Vincent T., Antin, Joseph H., Joyce, Robin, Cutler, Corey, Gooptu, Mahasweta, Nikiforow, Sarah, Logan, Emma K., Elavalakanar, Pavania, Narcis, Michele, Stroopinsky, Dina, Avigan, Zachary M., Boussi, Leora, Stephenson, Susan, El Banna, Hassan, Bindal, Poorva, Cheloni, Giulia, Avigan, David E., Soiffer, Robert J., and Rosenblatt, Jacalyn

Published
2023
Full Text
View/download PDF

2. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Author

Penter, Livius, Liu, Yang, Wolff, Jacquelyn O., Yang, Lin, Taing, Len, Jhaveri, Aashna, Southard, Jackson, Patel, Manishkumar, Cullen, Nicole M., Pfaff, Kathleen L., Cieri, Nicoletta, Oliveira, Giacomo, Kim-Schulze, Seunghee, Ranasinghe, Srinika, Leonard, Rebecca, Robertson, Taylor, Morgan, Elizabeth A., Chen, Helen X., Song, Minkyung H., Thurin, Magdalena, Li, Shuqiang, Rodig, Scott J., Cibulskis, Carrie, Gabriel, Stacey, Bachireddy, Pavan, Ritz, Jerome, Streicher, Howard, Neuberg, Donna S., Hodi, F. Stephen, Davids, Matthew S., Gnjatic, Sacha, Livak, Kenneth J., Altreuter, Jennifer, Michor, Franziska, Soiffer, Robert J., Garcia, Jacqueline S., and Wu, Catherine J.

Published
2023
Full Text
View/download PDF

4. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Author

Murdock, H. Moses, Kim, Haesook T., Denlinger, Nathan, Vachhani, Pankit, Hambley, Bryan, Manning, Bryan S., Gier, Shannon, Cho, Christina, Tsai, Harrison K., McCurdy, Shannon, Ho, Vincent T., Koreth, John, Soiffer, Robert J., Ritz, Jerome, Carroll, Martin P., Vasu, Sumithira, Perales, Miguel-Angel, Wang, Eunice S., Gondek, Lukasz P., Devine, Steven, Alyea, Edwin P., III, Lindsley, R. Coleman, and Gibson, Christopher J.

Published
2022
Full Text
View/download PDF

5. BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes

Author

Zaiken, Michael C., Flynn, Ryan, Paz, Katelyn G., Rhee, Stephanie Y., Jin, Sujeong, Mohamed, Fathima A., Saha, Asim, Thangavelu, Govindarajan, Park, Paul M.C., Hemming, Matthew L., Sage, Peter T., Sharpe, Arlene H., DuPage, Michel, Bluestone, Jeffrey A., Panoskaltsis-Mortari, Angela, Cutler, Corey S., Koreth, John, Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome, Luznik, Leo, Maillard, Ivan, Hill, Geoffrey R., MacDonald, Kelli P.A., Munn, David H., Serody, Jonathan S., Murphy, William J., Kean, Leslie S., Zhang, Yi, Bradner, James E., Qi, Jun, and Blazar, Bruce R.

Published
2022
Full Text
View/download PDF

7. Ischemic Stroke in Children and Young Adults with Sickle Cell Disease (SCD) in the Post-STOP Era

Author

Kwiatkowski, Janet L, Kanter, Julie, Fullerton, Heather J, Voeks, Jenifer, Debenham, Ellen, Brown, David G, Brown, Lynette J, and Adams, Robert J

Subjects
Brain Disorders, Stroke, Rare Diseases, Hematology, Sickle Cell Disease, Pediatric, Neurosciences, Clinical Trials and Supportive Activities, Prevention, Clinical Research, Health Services, Biomedical Imaging, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract

Abstract Background: The Stroke Prevention Trial in Sickle Cell Anemia (STOP) and Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) established routine transcranial Doppler ultrasound (TCD) screening with indefinite chronic red cell transfusions (CRCT) for children with abnormal TCD as standard of care. To identify children at high-risk of stroke, annual TCD screening is recommended from ages 2 to 16 years, with more frequent monitoring if the result is not normal. A reduction in stroke incidence in children with SCD has been reported in several clinical series and analyses utilizing large hospital databases when comparing rates before and after the publication of the STOP study in 1998. We sought to determine the rate of first ischemic stroke in a multicenter cohort of children who had previously participated in the STOP and/or STOP 2 trials and to determine whether these strokes were screening or treatment failures. Subjects and Methods: Between 1995 and 2005, STOP and STOP 2 (STOP/2) were conducted at 26 sites in the US and Canada. These studies included 3,835 children, ages 2 to 16 y with SCD type SS or S-beta-0-thalassemia. Participation in STOP/2 ranged from a single screening TCD to randomization. STOP 2 also had an observational arm for children on CRCT for abnormal TCD whose TCD had not reverted to normal. The Post-STOP study was designed to follow-up the outcomes of children who participated in one or both trials. 19 of the 26 original study sites participated in Post-STOP, contributing a total of 3,539 (92%) of the STOP/2 subjects. After exit from STOP/2, these children received TCD screening and treatment according to local practices. Data abstractors visited each clinical site and obtained retrospective data from STOP/2 study exit to 2012-2014 (depending on site) including follow-up TCD and brain imaging results, clinical information, and laboratory results. Two vascular neurologists, blinded to STOP/2 status and prior TCD and neuroimaging results, reviewed source records to confirm all ischemic strokes, defined as a symptomatic cerebral infarction; discordant opinions were resolved through discussion. For the first Post-STOP ischemic stroke, prior TCD result and treatment history subsequently were analyzed. Results: Of the 3,539 subjects, follow-up data were available for 2,850 (81%). Twelve children who had a stroke during STOP or STOP2 were excluded from these analyses resulting in data on 2,838 subjects. The mean age at the start of Post-STOP was 10.5 y and mean duration of follow-up after exiting STOP/2 was 9.1 y. A total of 69 first ischemic strokes occurred in the Post-STOP observation period (incidence 0.27 per 100 pt years). The mean age at time of stroke was 14.4±6.2 (median 13.8, range 3.5-28.9) y. Twenty-five of the 69 patients (36%) had documented abnormal TCD (STOP/2 or Post-STOP) prior to the stroke; 15 (60%) were receiving CRCT and 9 (36%) were not (treatment data not available for 1 subject). Among the 44 subjects without documented abnormal TCD, 29 (66%) had not had TCD re-screen in the Post-STOP period prior to the event; 7 of these 29 (24%) were 16 y or older at the start of Post-STOP, which is beyond the recommended screening age. Four of the 44 (9%) patients had inadequate TCD in Post-STOP (1 to 10.7 y prior to event). Six (14%) had normal TCD more than a year before the event (1.2 - 4 y); all but one of these children were younger than 16 y at the time of that TCD. Only 5 (11%) had a documented normal TCD less than 1 year prior to the event. Conclusions: In the Post-STOP era, the rate of first ischemic stroke was substantially lower than that reported in the Cooperative Study of Sickle Cell Disease, prior to implementation of TCD screening. Many (39%) of the Post-STOP ischemic strokes were associated with a failure to re-screen according to current guidelines, while only 11% occurred in children who had had recent low-risk TCD. Among those known to be at high risk prior to stroke, treatment refusal or inadequate treatment may have contributed. While TCD screening and treatment are effective at reducing ischemic stroke in clinical practice, significant gaps in screening and treatment, even at sites experienced in the STOP protocol, remain to be addressed. Closing these gaps should provide yet further reduction of ischemic stroke in SCD. Disclosures No relevant conflicts of interest to declare.

Published
2015

9. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Author

Livius Penter, Yang Liu, Jacquelyn O. Wolff, Lin Yang, Len Taing, Aashna Jhaveri, Jackson Southard, Manishkumar Patel, Nicole M. Cullen, Kathleen L. Pfaff, Nicoletta Cieri, Giacomo Oliveira, Seunghee Kim-Schulze, Srinika Ranasinghe, Rebecca Leonard, Taylor Robertson, Elizabeth A. Morgan, Helen X. Chen, Minkyung H. Song, Magdalena Thurin, Shuqiang Li, Scott J. Rodig, Carrie Cibulskis, Stacey Gabriel, Pavan Bachireddy, Jerome Ritz, Howard Streicher, Donna S. Neuberg, F. Stephen Hodi, Matthew S. Davids, Sacha Gnjatic, Kenneth J. Livak, Jennifer Altreuter, Franziska Michor, Robert J. Soiffer, Jacqueline S. Garcia, and Catherine J. Wu

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Abstract

The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML) after initial cytoreduction has motivated modern efforts to combine synergistic active modalities including immunotherapy. Recently, the ETCTN/CTEP 10026 study tested the combination of the DNA methyltransferase inhibitor decitabine together with the immune checkpoint inhibitor ipilimumab for AML/myelodysplastic syndrome (MDS) either after allogeneic hematopoietic stem cell transplantation (HSCT) or in the HSCT-naïve setting. Integrative transcriptome-based analysis of 304 961 individual marrow-infiltrating cells for 18 of 48 subjects treated on study revealed the strong association of response with a high baseline ratio of T to AML cells. Clinical responses were predominantly driven by decitabine-induced cytoreduction. Evidence of immune activation was only apparent after ipilimumab exposure, which altered CD4+ T-cell gene expression, in line with ongoing T-cell differentiation and increased frequency of marrow-infiltrating regulatory T cells. For post-HSCT samples, relapse could be attributed to insufficient clearing of malignant clones in progenitor cell populations. In contrast to AML/MDS bone marrow, the transcriptomes of leukemia cutis samples from patients with durable remission after ipilimumab monotherapy showed evidence of increased infiltration with antigen-experienced resident memory T cells and higher expression of CTLA-4 and FOXP3. Altogether, activity of combined decitabine and ipilimumab is impacted by cellular expression states within the microenvironmental niche of leukemic cells. The inadequate elimination of leukemic progenitors mandates urgent development of novel approaches for targeting these cell populations to generate long-lasting responses. This trial was registered at www.clinicaltrials.gov as #NCT02890329.

Published
2023
Full Text
View/download PDF

11. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Author

Nahas, Myrna R., Soiffer, Robert J., Kim, Haesook T., Alyea, Edwin P., III, Arnason, Jon, Joyce, Robin, Antin, Joseph H., Ho, Vincent T., Stroopinsky, Dina, Li, Shuli, Levine, James D., McMasters, Malgorzata, Jain, Salvia, Hamdan, Ayad, Tzachanis, Dimitrios, Bryant, Mary Paty, Logan, Emma K., Bazemore, Josie, Stewart, Jeremy, Joyce, Amy, Stephenson, Susan, Washington, Abigail, Cole, Leandra, Pyzer, Athalia, Leaf, Rebecca Karp, Avigan, David E., and Rosenblatt, Jacalyn

Published
2018
Full Text
View/download PDF

14. Somatic mutations and clonal hematopoiesis in congenital neutropenia

Author

Xia, Jun, Miller, Christopher A., Baty, Jack, Ramesh, Amrita, Jotte, Matthew R.M., Fulton, Robert S., Vogel, Tiphanie P., Cooper, Megan A., Walkovich, Kelly J., Makaryan, Vahagn, Bolyard, Audrey A., Dinauer, Mary C., Wilson, David B., Vlachos, Adrianna, Myers, Kasiani C., Rothbaum, Robert J., Bertuch, Alison A., Dale, David C., Shimamura, Akiko, Boxer, Laurence A., and Link, Daniel C.

Published
2018
Full Text
View/download PDF

15. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Author

Hayashi, Robert J., Hermiston, Michelle L., Wood, Brent L., Teachey, David T., Devidas, Meenakshi, Chen, Zhiguo, Annett, Robert D., Asselin, Barbara L., August, Keith, Cho, Steve, Dunsmore, Kimberly P., Freedman, Jason Lawrence, Galardy, Paul J., Harker-Murray, Paul, Horton, Terzah M., Jaju, Alok, Lam, Allison, Messinger, Yoav H., Miles, Rodney R., Okada, Maki, Patel, Samir, Schafer, Eric S., Schechter, Tal, Shimano, Kristin A., Singh, Neelam, Steele, Amii, Sulis, Maria L., Vargas, Sarah L., Winter, Stuart S., Wood, Charlotte, Zweidler-McKay, Patrick A., Loh, Mignon L., Hunger, Stephen P., Raetz, Elizabeth A., Bollard, Catherine M., and Allen, Carl E.

Published
2024
Full Text
View/download PDF

20. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Author

Merryman, Reid W., Kim, Haesook T., Zinzani, Pier Luigi, Carlo-Stella, Carmelo, Ansell, Stephen M., Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad S., Houot, Roch, Marchand, Tony, Dhedin, Nathalie, Lescaut, Willy, Thiebaut-Bertrand, Anne, François, Sylvie, Stamatoullas-Bastard, Aspasia, Rohrlich, Pierre-Simon, Labussière Wallet, Hélène, Castagna, Luca, Santoro, Armando, Bachanova, Veronika, Bresler, Scott C., Srivastava, Amitabh, Kim, Harim, Pesek, Emily, Chammas, Marie, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J., and Armand, Philippe

Published
2017
Full Text
View/download PDF

21. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Author

Grever, Michael R., Abdel-Wahab, Omar, Andritsos, Leslie A., Banerji, Versha, Barrientos, Jacqueline, Blachly, James S., Call, Timothy G., Catovsky, Daniel, Dearden, Claire, Demeter, Judit, Else, Monica, Forconi, Francesco, Gozzetti, Alessandro, Ho, Anthony D., Johnston, James B., Jones, Jeffrey, Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Larratt, Loree, Lauria, Francesco, Lozanski, Gerard, Montserrat, Emili, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme R., Rai, Kanti R., Ravandi, Farhad, Robak, Tadeusz, Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine, Tiacci, Enrico, Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, and Falini, Brunangelo

Published
2017
Full Text
View/download PDF

22. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Author

Garcia, Jacqueline S., primary, Flamand, Yael, additional, Penter, Livius, additional, Keng, Michael, additional, Tomlinson, Benjamin K., additional, Mendez, Lourdes M., additional, Koller, Paul, additional, Cullen, Nicole, additional, Arihara, Yohei, additional, Pfaff, Kathleen, additional, Wolff, Jacquelyn O., additional, Brunner, Andrew M., additional, Galinsky, Ilene, additional, Bashey, Asad, additional, Antin, Joseph H., additional, Cutler, Corey, additional, Ho, Vincent, additional, Jonas, Brian A., additional, Luskin, Marlise R., additional, Wadleigh, Martha, additional, Winer, Eric S., additional, Savell, Alexandra, additional, Leonard, Rebecca, additional, Robertson, Taylor, additional, Davids, Matthew S., additional, Streicher, Howard, additional, Rodig, Scott J., additional, Ritz, Jerome, additional, Wu, Catherine J., additional, DeAngelo, Daniel J., additional, Neuberg, Donna, additional, Stone, Richard M., additional, and Soiffer, Robert J., additional

Published
2023
Full Text
View/download PDF

23. Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

Author

Xiang, Michael, Kim, Haesook, Ho, Vincent T., Walker, Sarah R., Bar-Natan, Michal, Anahtar, Melodi, Liu, Suhu, Toniolo, Patricia A., Kroll, Yasmin, Jones, Nichole, Giaccone, Zachary T., Heppler, Lisa N., Ye, Darwin Q., Marineau, Jason J., Shaw, Daniel, Bradner, James E., Blonquist, Traci, Neuberg, Donna, Hetz, Claudio, Stone, Richard M., Soiffer, Robert J., and Frank, David A.

Published
2016
Full Text
View/download PDF

26. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease

Author

Koreth, John, Kim, Haesook T., Jones, Kyle T., Lange, Paulina B., Reynolds, Carol G., Chammas, Marie J., Dusenbury, Katherine, Whangbo, Jennifer, Nikiforow, Sarah, Alyea, Edwin P., III, Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Chen, Yi-Bin, Avigan, David, Blazar, Bruce R., Antin, Joseph H., Ritz, Jerome, and Soiffer, Robert J.

Published
2016
Full Text
View/download PDF

28. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Author

Richardson, Paul G., Riches, Marcie L., Kernan, Nancy A., Brochstein, Joel A., Mineishi, Shin, Termuhlen, Amanda M., Arai, Sally, Grupp, Stephan A., Guinan, Eva C., Martin, Paul L., Steinbach, Gideon, Krishnan, Amrita, Nemecek, Eneida R., Giralt, Sergio, Rodriguez, Tulio, Duerst, Reggie, Doyle, John, Antin, Joseph H., Smith, Angela, Lehmann, Leslie, Champlin, Richard, Gillio, Alfred, Bajwa, Rajinder, D’Agostino Sr, Ralph B., Massaro, Joseph, Warren, Diane, Miloslavsky, Maja, Hume, Robin L., Iacobelli, Massimo, Nejadnik, Bijan, Hannah, Alison L., and Soiffer, Robert J.

Published
2016
Full Text
View/download PDF

30. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy

Author

Kollman, Craig, Spellman, Stephen R., Zhang, Mei-Jie, Hassebroek, Anna, Anasetti, Claudio, Antin, Joseph H., Champlin, Richard E., Confer, Dennis L., DiPersio, John F., Fernandez-Viña, Marcelo, Hartzman, Robert J., Horowitz, Mary M., Hurley, Carolyn K., Karanes, Chatchada, Maiers, Martin, Mueller, Carlheinz R., Perales, Miguel-Angel, Setterholm, Michelle, Woolfrey, Ann E., Yu, Neng, and Eapen, Mary

Published
2016
Full Text
View/download PDF

32. Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets

Author

Nicoletta Cieri, Nidhi Hookeri, Kari Stromhaug, Jonathan Stevens, Kameron Kooshesh, Susan Klaeger, Karl R. Clauser, Siranush Sarkizova, David A. Braun, Livius Penter, Giacomo Oliveira, Haesook T. Kim, William J. Lane, Shuqiang Li, Kenneth J. Livak, Vincent T. Ho, Jerome Ritz, Robert J. Soiffer, Derin B. Keskin, Chip Stewart, Alexander Gusev, Gad Getz, and Catherine J. Wu

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

33. Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Author

Robert J. Hayashi, Michelle L. Hermiston, David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert D Annett, Barbara L Asselin, Keith J August, Steve Y Cho, Kimberly P. Dunsmore, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok I Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir I Patel, Eric S Schafer, Tal Schechter-Finkelstein, Kristin A. Shimano, Neelam Singh, Amii C. Steele, Maria Luisa Sulis, Sarah L Vargas, Stuart S. Winter, Charlotte Wood, Patrick A Zweidler-McKay, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz, Catherine M Bollard, and Carl Allen

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

34. Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

Author

Lachelle D. Weeks, Abhishek Niroula, Donna S. Neuberg, Waihay J. Wong, R. Coleman Lindsley, Marlise R. Luskin, Nancy Berliner, Richard M. Stone, Daniel J DeAngelo, Robert J Soiffer, Md Mesbah Uddin, Christopher J. Gibson, Alexander G. Bick, Gabriel K. Griffin, Siddhartha Jaiswal, Luca Malcovati, Pradeep Natarajan, and Benjamin L. Ebert

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

35. Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Author

Jacqueline S. Garcia, Haesook T Kim, Jennifer Brock, H. Moses Murdock, Corey S. Cutler, Daniel J. DeAngelo, Christopher J. Gibson, Mahasweta Gooptu, Vincent Ho, John Koreth, Marlise R. Luskin, Sarah Nikiforow, Rizwan Romee, Roman M Shapiro, Richard M. Stone, Martha Wadleigh, Eric S. Winer, Michela Ansuinelli, Eliza Elliot, Geoffrey Fell, Hannah Karp, Jeremy Ryan, Anthony G. Letai, Coleman Lindsley, Robert J Soiffer, Joseph H. Antin, Fiona Loschi, and Jerome Ritz

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

36. Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study

Author

Zhiwei Liu, Yang Luo, Samuel Kirimunda, Murielle Verboom, Olusegun O Onabajo, Mateus H Gouveia, Martin Ogwang, Patrick Kerchan, Steven Reynolds, Constance N Tenge, Pamela A Were, Robert T Kuremu, Walter N Wekesa, Nestory Masalu, Esther Kawira, Tobias Kinyera, Isaac Otim, Ismail D Legason, Hadijah Nabalende, Herry Dhudha, Leona W Ayers, Robert J Biggar, Kishor G. Bhatia, James J Goedert, Nathan Cole, Wen Luo, Jia Liu, Michelle Manning, Belynda Hicks, Ludmila Prokunina-Olsson, George Chagaluka, Tom Johnston, Nora Mutalima, Eric Borgstein, George N Liomba, Steve Kamiza, Nyengo Mkandawire, Collins Mitambo, Elizabeth Molyneux, Robert Newton, Ann W Hsing, James E Mensah, Ruth M Pfeiffer, Amy Hutchinson, Carrington Mary, Meredith Yeager, Moses Joloba, Rainer Blasczyk, Stephen J. Chanock, Soumya Raychaudhuri, and Sam M. Mbulaiteye

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

37. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Author

H. Moses Murdock, Haesook T. Kim, Nathan Denlinger, Pankit Vachhani, Bryan Hambley, Bryan S. Manning, Shannon Gier, Christina Cho, Harrison K. Tsai, Shannon McCurdy, Vincent T. Ho, John Koreth, Robert J. Soiffer, Jerome Ritz, Martin P. Carroll, Sumithira Vasu, Miguel-Angel Perales, Eunice S. Wang, Lukasz P. Gondek, Steven Devine, Edwin P. Alyea, R. Coleman Lindsley, and Christopher J. Gibson

Subjects
Transplantation, Neoplasm, Residual, Transplantation Conditioning, Immunology, Hematopoietic Stem Cell Transplantation, Cell Biology, Hematology, Biochemistry, Leukemia, Myeloid, Acute, Recurrence, hemic and lymphatic diseases, Humans, Transplantation, Homologous, Aged, Retrospective Studies
Abstract

Older patients with acute myeloid leukemia (AML) have high relapse risk and poor survival after allogeneic hematopoietic cell transplantation (HCT). Younger patients may receive myeloablative conditioning to mitigate relapse risk associated with high-risk genetics or measurable residual disease (MRD), but older adults typically receive reduced-intensity conditioning (RIC) to limit toxicity. To identify factors that drive HCT outcomes in older patients, we performed targeted mutational analysis (variant allele fraction ≥2%) on diagnostic samples from 295 patients with AML aged ≥60 years who underwent HCT in first complete remission, 91% of whom received RIC, and targeted duplex sequencing at remission in a subset comprising 192 patients. In a multivariable model for leukemia-free survival (LFS) including baseline genetic and clinical variables, we defined patients with low (3-year LFS, 85%), intermediate (55%), high (35%), and very high (7%) risk. Before HCT, 79.7% of patients had persistent baseline mutations, including 18.3% with only DNMT3A or TET2 (DT) mutations and 61.4% with other mutations (MRD positive). In univariable analysis, MRD positivity was associated with increased relapse and inferior LFS, compared with DT and MRD-negative mutations. However, in a multivariable model accounting for baseline risk, MRD positivity had no independent impact on LFS, most likely because of its significant association with diagnostic genetic characteristics, including MDS-associated gene mutations, TP53 mutations, and high-risk karyotype. In summary, molecular associations with MRD positivity and transplant outcomes in older patients with AML are driven primarily by baseline genetics, not by mutations present in remission. In this group of patients, where high-intensity conditioning carries substantial risk of toxicity, alternative approaches to mitigating MRD-associated relapse risk are needed.

Published
2022
Full Text
View/download PDF

38. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease

Author

Koshy, Anita G., primary, Kim, Haesook T., additional, Liegel, Jessica, additional, Arnason, Jon E., additional, Ho, Vincent T., additional, Antin, Joseph H., additional, Joyce, Robin, additional, Cutler, Corey S., additional, Gooptu, Mahasweta, additional, Nikiforow, Sarah, additional, Logan, Emma K., additional, Elavalakanar, Pavania, additional, Narcis, Michele, additional, Stroopinsky, Dina, additional, Avigan, Zachary M., additional, Boussi, Leora, additional, Stephenson, Susan L, additional, El Banna, Hassan, additional, Bindal, Poorva, additional, Cheloni, Giulia, additional, Avigan, David E., additional, Soiffer, Robert J., additional, and Rosenblatt, Jacalyn, additional

Published
2023
Full Text
View/download PDF

42. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease

Author

Flynn, Ryan, Allen, Jessica L., Luznik, Leo, MacDonald, Kelli P., Paz, Katelyn, Alexander, Kylie A., Vulic, Ante, Du, Jing, Panoskaltsis-Mortari, Angela, Taylor, Patricia A., Poe, Jonathan C., Serody, Jonathan S., Murphy, William J., Hill, Geoffrey R., Maillard, Ivan, Koreth, John, Cutler, Corey S., Soiffer, Robert J., Antin, Joseph H., Ritz, Jerome, Chao, Nelson J., Clynes, Raphael A., Sarantopoulos, Stefanie, and Blazar, Bruce R.

Published
2015
Full Text
View/download PDF

46. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease

Author

Anita G. Koshy, Haesook T. Kim, Jessica Liegel, Jon E. Arnason, Vincent T. Ho, Joseph H. Antin, Robin Joyce, Corey S. Cutler, Mahasweta Gooptu, Sarah Nikiforow, Emma K. Logan, Pavania Elavalakanar, Michele Narcis, Dina Stroopinsky, Zachary M. Avigan, Leora Boussi, Susan L Stephenson, Hassan El Banna, Poorva Bindal, Giulia Cheloni, David E. Avigan, Robert J. Soiffer, and Jacalyn Rosenblatt

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Abstract

Steroid-refractory chronic graft versus host disease (cGVHD) remains a significant cause of morbidity and mortality following allogeneic transplantation. Abatacept is a selective co-stimulation modulator, used for the treatment of rheumatologic disease, and was recently the first drug to be approved by the FDA for the prophylaxis of acute graft versus host disease. We conducted a Phase II study to evaluate the efficacy of Abatacept in steroid-refractory cGVHD (clinicaltrials.gov #NCT01954979). The overall response rate was 58%, with all responders achieving a partial response. Abatacept was well-tolerated with few serious infectious complications. Immune correlative studies showed a decrease in IL-1-alpha, IL-21, and TNF-alpha as well as decreased PD-1 expression by CD4+ T cells in all patients after treatment with Abatacept, demonstrating the effect of this drug on the immune microenvironment. The results demonstrate that Abatacept is a promising therapeutic strategy for the treatment of cGVHD.

Published
2023
Full Text
View/download PDF

48. Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings

Author

Jacqueline S. Garcia, Yael Flamand, Livius Penter, Michael Keng, Benjamin K. Tomlinson, Lourdes M. Mendez, Paul Koller, Nicole Cullen, Yohei Arihara, Kathleen Pfaff, Jacquelyn O. Wolff, Andrew M. Brunner, Ilene Galinsky, Asad Bashey, Joseph H. Antin, Corey Cutler, Vincent Ho, Brian A. Jonas, Marlise R. Luskin, Martha Wadleigh, Eric S. Winer, Alexandra Savell, Rebecca Leonard, Taylor Robertson, Matthew S. Davids, Howard Streicher, Scott J. Rodig, Jerome Ritz, Catherine J. Wu, Daniel J. DeAngelo, Donna Neuberg, Richard M. Stone, and Robert J. Soiffer

Subjects
Immunology, Cell Biology, Hematology, Letter to Blood, Biochemistry
Abstract

Two articles in this week’s issue focus on the use of ipilimumab and decitabine for patients with myelodysplasia (MDS) and acute myeloid leukemia (AML) before and after hematopoietic stem cell transplantation (HSCT) for high-risk disease. In the first article, Garcia et al report on the results of a phase 1 trial of the combination in 54 patients, demonstrating overall response rate of 52% in patients who are HSCT-naïve and 20% in patients post-HSCT; responses are usually short-lived. In the second article, Penter and colleagues characterize gene expression responses to therapy and conclude that decitabine acts directly to clear leukemic cells while ipilimumab acts on infiltrating lymphocytes in marrow and extramedullary sites. Responses are determined by leukemic cell burden and by the frequency and phenotype of infiltrating lymphocytes. Increasing bone marrow regulatory T cells is identified as a potential contributor to checkpoint inhibitor escape.

Published
2022

50. Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis

Author

Verstovsek, Srdan, primary, Mascarenhas, John, additional, Rampal, Raajit K, additional, Cilloni, Daniela, additional, Harrison, Claire, additional, Jacoby, Brian, additional, Slack, Robert J., additional, Aslanis, Vassilios, additional, Singh, Bobby, additional, and Lindmark, Bertil, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results